From the Department of Radiation Oncology & Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, Baltimore, Maryland.
J Natl Compr Canc Netw. 2015 May;13(5):597-605. doi: 10.6004/jnccn.2015.0077.
The advent of effective combination chemotherapy markedly changed the management of Hodgkin lymphoma, establishing combined modality therapy as the standard of care for most patients with this disease. In response, significant interest has been shown in refining the delivery of radiation in the combined modality setting such that toxicity is minimized while still preserving disease control. An understanding of the way in which radiation treatment fields, prescription dose, and advanced technology have evolved to accomplish these goals is critical. Moreover, fluency in the clinical literature exploring contemporary questions, such as the omission of radiation and response-based treatment, is equally important. Knowledge of these topics will yield both an appreciation of the value of radiation in the combined modality setting and the ability to better customize treatment regimens to individual patients.
有效的联合化疗的出现显著改变了霍奇金淋巴瘤的治疗方式，使联合治疗成为大多数此类患者的标准治疗方案。有鉴于此，人们对如何改进联合治疗中的放疗方法产生了浓厚的兴趣，以期在控制疾病的同时，将毒性降至最低。因此，了解放疗野、处方剂量和先进技术的发展方式对于实现这些目标至关重要。此外，熟悉探索当代问题的临床文献也同样重要，例如放疗的省略和基于反应的治疗。掌握这些知识不仅可以让人们更好地理解放疗在联合治疗中的价值，还能帮助医生更好地为每位患者制定治疗方案。
